The mutational landscape was described by pretreatment WES data from 8 patients, combining TMB, TNB, MSI, HLA-LOH, and PD-L1 expressions, sarcoma types, and anti-PD-1 clinical responses (Figures 1B and 3A). The gene discussed is CD274; the disease is sarcoma.